PCSK9 and cardiovascular disorder: In 2020 a recent sub analysis of the FOURIER and ODYSSEY OUTCOMES trials revealed that PCSK9 inhibition in patients with stable atherosclerosis and hyperlipidemia on statin therapy significantly reduces the risk of venous thromboembolism supporting a protective role for antiPCSK9 antibodies in human cardiovascular diseases (92).